PSP-CBD Overlap Syndrome

PSP-CBD Overlap Syndrome

Overview

The relationship between Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) represents one of the most clinically and pathologically complex intersections in the spectrum of 4R tauopathies. While these disorders were historically described as distinct entities, accumulating evidence demonstrates significant clinical, pathological, and genetic overlap, leading to the recognition of a spectrum of disorders rather than strictly separable diseases.

The PSP-CBD overlap syndrome presents unique challenges for clinicians and researchers, as patients may exhibit features of both disorders simultaneously or transition between clinical phenotypes over time. This overlap has profound implications for diagnosis, prognostic counseling, clinical trial design, and therapeutic development.

Historical Context and Evolution of Concepts

Historical Separation

Initially, PSP and CBD were described as distinct clinical syndromes with characteristic pathological features:

• PSP (Steele-Richardson-Olszewski syndrome): First described in 1964 as a distinct disorder characterized by vertical gaze palsy, postural instability, and parkinsonism
• CBD: Described as a progressive asymmetric movement disorder with apraxia, cortical sensory loss, and alien limb phenomenon

Convergence of Understanding

Modern understanding has evolved to recognize these as related disorders within the 4R tauopathy spectrum:

...

PSP-CBD Overlap Syndrome

Overview

The relationship between Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) represents one of the most clinically and pathologically complex intersections in the spectrum of 4R tauopathies. While these disorders were historically described as distinct entities, accumulating evidence demonstrates significant clinical, pathological, and genetic overlap, leading to the recognition of a spectrum of disorders rather than strictly separable diseases.

The PSP-CBD overlap syndrome presents unique challenges for clinicians and researchers, as patients may exhibit features of both disorders simultaneously or transition between clinical phenotypes over time. This overlap has profound implications for diagnosis, prognostic counseling, clinical trial design, and therapeutic development.

Historical Context and Evolution of Concepts

Historical Separation

Initially, PSP and CBD were described as distinct clinical syndromes with characteristic pathological features:

• PSP (Steele-Richardson-Olszewski syndrome): First described in 1964 as a distinct disorder characterized by vertical gaze palsy, postural instability, and parkinsonism
• CBD: Described as a progressive asymmetric movement disorder with apraxia, cortical sensory loss, and alien limb phenomenon

Convergence of Understanding

Modern understanding has evolved to recognize these as related disorders within the 4R tauopathy spectrum:

• Both are characterized by accumulation of 4-repeat tau isoforms
• Both share common genetic risk factors (primarily MAPT H1 haplotype)
• Both demonstrate similar patterns of neuronal and glial tau pathology
• Clinical phenotypes can manifest overlapping features or transition between presentations

Clinical Overlap

Shared Clinical Features

Both PSP and CBD demonstrate significant overlap in their clinical presentations[@ling2023]:

| Feature | PSP | CBD | Overlap |
|---------|-----|-----|--------|
| Parkinsonism | Prominent | Asymmetric, prominent | Both show parkinsonian features |
| Cognitive dysfunction | Frontal executive | Cortical, language | Both develop cognitive decline |
| Axial rigidity | Prominent (cockroach posture) | Limb rigidity | Both show rigidity |
| Gait impairment | Early, prominent | Variable, late | Both ultimately affected |
| Oculomotor dysfunction | Vertical gaze palsy | Variable | Overlapping but not identical |

PSP-CBS Phenotype

The PSP presenting with corticobasal syndrome (PSP-CBS) represents the most well-characterized overlap phenotype[@armstrong2013]:

Clinical Characteristics:

• Asymmetric onset of symptoms
• Prominent apraxia (limb kinetic apraxia)
• Cortical sensory loss (impaired two-point discrimination, stereognosis)
• Alien limb phenomenon
• Myoclonus (cortical origin)
• Early language impairment

Distinguishing Features from Classic PSP:

• Asymmetric presentation (vs. symmetric in PSP-RS)
• Prominent cortical signs (less common in classic PSP)
• Earlier onset of cognitive/behavioral changes

Distinguishing Features from Classic CBD:

• More prominent axial symptoms
• Earlier gait impairment
• More symmetric oculomotor findings eventually

Phenotypic Switching

A notable phenomenon in the overlap spectrum is the potential for clinical phenotype transition over time:

• Patients initially presenting as PSP may develop corticobasal features
• Patients initially diagnosed with CBD may develop classic PSP features
• This phenotypic plasticity reflects the underlying shared tau pathology

Pathological Overlap

Tau Pathology Patterns

Both PSP and CBD demonstrate 4R tau pathology, but with distinct patterns[@dickson2010]:

PSP Pathological Hallmarks:

• Globose neurofibrillary tangles: Located in subthalamic nucleus, globus pallidus, substantia nigra
• Tufted astrocytes: Particularly in the striatum and cortex
• Coiled bodies: Oligodendroglial tau inclusions
• Thread-like processes: Distributing throughout affected regions

CBD Pathological Hallmarks:

• Cortical neuronal loss and ballooned neurons: Widespread in affected cortical regions
• Astrocytic plaques: Distinct from the tufted astrocytes of PSP
• Achromatic cells: Ballooned neurons in cortical gray matter
• Coiled bodies: Present in white matter

Shared Features:

• Both show 4R tau accumulation
• Both involve oligodendroglial pathology
• Both demonstrate neuronal loss in affected regions

Regional Vulnerability

The distribution of tau pathology differs between PSP and CBD, explaining the clinical differences:

| Brain Region | PSP | CBD |
|--------------|-----|-----|
| Brainstem | Severe (midbrain, pontine nuclei) | Variable |
| Basal ganglia | Severe (STN, GP, SN) | Moderate |
| Cortex | Moderate (frontal > other) | Severe (frontoparietal) |
| Cerebellum | Moderate | Variable |

Molecular Classification

Recent advances in cryo-electron microscopy have revealed distinct tau filament structures[@fitzpatrick2017]:

• PSP tau filament: C-shaped, three-layered assembly
• CBD tau filament: Distinct double-C-shaped structure

These structural differences support the concept of distinct "tau strains" while acknowledging the clinical overlap.

Genetic Overlap

Shared Genetic Risk Factors

Genetic studies have identified significant overlap in risk factors for PSP and CBD[@chen2021]:

MAPT H1 Haplotype:

• Primary genetic risk factor for both disorders
• H1/H1 genotype associated with increased risk for both PSP and CBD
• H1 subhaplotypes may influence phenotype expression

Other Shared Risk Loci:

• MOBP: Myelin-associated oligodendrocyte basic protein
• STX6: Syntaxin-6
• EIF2AK3: Endoplasmic reticulum stress response gene
• SLCO1A2: Organic anion transporter

Distinguishing Genetic Factors

While significant overlap exists, some genetic factors may modify the phenotype:

• Specific MAPT mutations may favor one phenotype over another
• Genetic modifiers may influence age of onset and progression
• Polygenic risk scores show correlation between PSP and CBD risk

Biomarker Overlap and Differentiation

Cerebrospinal Fluid Biomarkers

CSF biomarker profiles show considerable overlap but some discriminative features[@blommer2024]:

| Biomarker | PSP | CBD | Notes |
|-----------|-----|-----|-------|
| Total tau | ↑ | ↑↑ | Higher in CBD |
| p-tau181 | Normal/↑ | ↑↑ (with AD) | Higher in CBD with AD co-pathology |
| p-tau217 | Normal | Variable | May detect AD co-pathology |
| NfL | ↑ | ↑↑ | Higher in CBD |
| GFAP | ↑ | ↑ | Similar elevation |

Key Insight: The combination of biomarkers (NfL + p-tau181 + Aβ42) achieves approximately 82% accuracy for differentiating PSP from CBD.

Neuroimaging Findings

Shared Imaging Features:

• Midbrain atrophy (more prominent in PSP)
• Frontal cortical atrophy
• Superior cerebellar peduncle involvement
• Basal ganglia abnormalities

Differentiating Features:

• PSP: More prominent midbrain atrophy ("hummingbird sign")
• CBD: More asymmetric cortical atrophy, particularly frontoparietal
• PSP-CBS: Features of both patterns

Tau PET Imaging

Modern tau PET ligands show differential binding patterns[@tau2021]:

• Flortaucipir (AV-1451): Shows binding in both PSP and CBD, with regional differences
• PI-2620: Shows promise for distinguishing 4R tauopathies
• ABBV-964i: Newer ligand under development specifically for 4R tau

Differential Diagnosis

Clinical Diagnostic Criteria

The Movement Disorder Society criteria for PSP and CBD acknowledge the overlap[@hglinger2017]:

PSP Diagnostic Criteria:

• Core features: Vertical gaze palsy, postural instability, parkinsonism
• Supportive features: Cognitive impairment, speech impairment
• Must rule out conditions that could explain symptoms

CBD Diagnostic Criteria:

• Core features: Asymmetric parkinsonism, apraxia, cortical sensory loss
• Supportive features: Alien limb, myoclonus, alien limb phenomenon

Challenge: Features supporting one diagnosis may be present in the other, leading to diagnostic uncertainty.

Practical Diagnostic Approach

A systematic approach to evaluating suspected PSP-CBD overlap:

Assess symmetry: More symmetric suggests PSP, more asymmetric suggests CBD

Evaluate cortical signs: Prominent apraxia, cortical sensory loss favors CBD

Assess oculomotor function: Early vertical gaze palsy favors PSP

Consider gait: Early falls and gait impairment favor PSP

Use biomarkers: CSF and imaging can provide supportive evidence

Follow longitudinally: Phenotype may evolve over time

Management Considerations

Symptomatic Treatment

Management approaches for PSP-CBD overlap are similar to both disorders[@stamelou2019]:

Pharmacological Approaches:

• Levodopa: May provide modest benefit, particularly in early stages
• Botulinum toxin: Effective for focal dystonia
• Clonazepam: For myoclonus and RBD
• SSRI antidepressants: For depression and pseudobulbar affect
• Cognitive enhancers: Modest benefit in some patients

Non-Pharmacological:

• Physical therapy for gait and balance
• Occupational therapy for functional independence
• Speech therapy for dysarthria and dysphagia
• Fall prevention strategies

Disease-Modifying Therapies

The overlap has implications for therapeutic development:

• Tau-targeted therapies: May benefit both conditions
• Clinical trial design: Overlap complicates patient selection
• Biomarker-driven trials: Need biomarkers that distinguish phenotypes
• Combination approaches: Targeting shared pathways

Research Implications

Clinical Trials

The PSP-CBD overlap has significant implications for clinical research:

Patient recruitment: Overlap syndromes may qualify for trials of either condition

Endpoint selection: May require endpoints sensitive to both phenotypes

Stratification: Biomarker-based stratification may improve trial power

Natural history: Phenotypic switching affects progression models

Biomarker Development

Current research priorities include:

• Developing biomarkers to distinguish PSP from CBD
• Identifying markers predicting phenotype evolution
• Tau PET ligands specific for 4R tauopathies
• Blood-based biomarkers for differential diagnosis

Therapeutic Targets

Shared therapeutic strategies for both conditions:

• Tau aggregation inhibitors: Target shared 4R tau pathology
• Anti-tau antibodies: May benefit both disorders
• ASO therapy: Targeting MAPT expression
• Neuroprotective strategies: Targeting shared pathways (mitochondrial dysfunction, neuroinflammation)

Cross-Links to Related Topics

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Primary disorder
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Related disorder
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms) — Shared pathophysiology
• [PSP Clinical Variants](/diseases/psp-clinical-variants) — Phenotypic spectrum
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) — Therapeutic evidence
• [MAPT Gene](/genes/mapt) — Shared genetic risk factor

References

[Boxer AL, Yu JT, Golbe LI, et al, Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches (2017)](https://pubmed.ncbi.nlm.nih.gov/28592453/)

[Respondek G, Höglinger GU, The phenotypic spectrum of progressive supranuclear palsy (2016)](https://pubmed.ncbi.nlm.nih.gov/26711656/)

[Ling H, Massey LA, Lees AJ, Atypical parkinsonism (2023)](https://pubmed.ncbi.nlm.nih.gov/26583255/)

[Armstrong MJ, Litvan I, Lang AE, et al, Criteria for the diagnosis of corticobasal degeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/23420531/)

[Dickson DW, Ahmed Z, Alghamdi A, et al, Neuropathology of corticobasal degeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20613640/)

[Fitzpatrick AWP, Falcon B, He S, et al, Cryo-EM structures of tau filaments from Alzheimer's disease brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28726765/)

[Chen JA, Chen Q, Yang G, et al, Shared genetic architecture between progressive supranuclear palsy and corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33249468/)

[Blommer R, Zetterberg H, van der Flier WM, et al, Combined CSF biomarker analysis for differential diagnosis of atypical parkinsonism (2024)](https://pubmed.ncbi.nlm.nih.gov/38933079/)

[Unknown, Tau PET imaging in 4R tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/33252462/)

[Höglinger GU, Respondek G, Stamelou M, et al, Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria (2017)](https://pubmed.ncbi.nlm.nih.gov/28467028/)

[Stamelou M, Höglinger GU, Review: Therapeutic approaches to progressive supranuclear palsy (2019)](https://pubmed.ncbi.nlm.nih.gov/31704935/)